Antioxidant and NMDA Receptor Blocker Wins Anoxic Brain Damage of KorEa OHCA Patients
A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 150 participants.
Also called NCT03651557
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 150 participants
- Sponsor
- Registry
-
NCT03651557
-
- Other papers using this trial's data
- Nelonemdaz Treatment for Patients With Out-of-Hospital Cardiac Arrest: A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- South Korea
- Registry status
- Unknown status
Technical summary
Registry record NCT03651557. Randomized; triple masking; primary purpose treatment. Start 2018-11-29 (actual); primary completion 2021-05 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Antioxidant and NMDA Receptor Blocker Wins Anoxic Brain Damage of KorEa OHCA Patients
- Acronym
- AWAKE
- Condition
- Cardiac Arrest
- Intervention (Drug)
- Neu2000KWL High-dose group
- Intervention (Drug)
- Neu2000KWL Low-dose group
- Intervention (Drug)
- Placebo
- Lead sponsor
- GNT Pharma
- Collaborator
- Samsung Medical Center
- Collaborator
- Chonnam National University Hospital
- Collaborator
- Gangnam Severance Hospital
- Collaborator
- Kyungpook National University Hospital
- Collaborator
- Pusan National University Hospital
- Collaborator
- Soonchunhyang University Hospital
Record details
- Record id
cardio:ct-nct03651557- Content hash
0011a7c6467a69a0cb99bfd968dba8fd9aa57324432ca6226724105a77dd7885